So, I think that it is in the area of cost control. I think that it is in the area of regulatory—they are probably the two biggest. No matter where you look in the world, there are barriers that we have to overcome. This puts the onus on the industry and this isn’t all bad. It puts the onus on us to do better work when we do our clinical trials, when we do our research and when we have full transparency and disclosure. I think that’s really important and I think that that comes from the ability of the regulatory bodies and the industry to work together. We’ve been advocates of strengthening the regulatory bodies, because the stronger they are in science, the stronger it will force us to be and the better it will be for patients. And, then with the cost side, we just have to be willing to step up. I think that the industry does support indigent people. We’ve actually supported in Sub-Sahara Africa our HTV products; we’ve made them available there at very low prices. If there are indigent patients here in the United States, they just have to file a form with us or any other pharmaceutical company and we will supply them with products free of charge if they qualify, which is a very low level to qualify. I think that we are doing all that we can, but we have to continue to do more.
所以，我認為它是存在于控制成本方面的。我認為這是在成本控制區(qū)，它們可能是兩個最大的。世界上總是存在我們必須克服的障礙。這就將責任歸到了工業(yè)方面，但這也不是沒有好處的。有了這項責任，我們就會在臨床試驗時做得更好，做研究做得更好，讓我們在完全的透明公開下做得更好。我覺得那很重要，要求監(jiān)察當局和我們的產業(yè)方面共同合作共同努力。我們一直提倡加強監(jiān)察當局的監(jiān)察力度，因為他們在科學方面越強大，就會促進我們的產業(yè)越強大，那就對我們的病人越有利。至于花費方面，我們不得不加快腳步。我想，產業(yè)總是會給貧困的人們一些資助。我們曾經給撒哈拉以南的地區(qū)資助過HIV產品，并且以很低的價格出售。如果在美國也有貧困病人的話，他只用給我們或其他藥品公司提交一個表格，如果他們有資格，我們也同樣會免費為他們提供產品，我想我們一直在盡我們所能來做這些事情，我們也會繼續(xù)做更多。
Reporter: Johnson and Johnson has operated in India for more than 50 years now. Recently, there was a big shake-up among drug companies there when the Japanese firm Daiichy Sankyo bought out Ranbaxy. What is your view on that deal and does it say anything about the state of the pharmaceutical industry in India?
記者：強生集團在印度已經經營了50多年的時間了。最近，你們的藥物公司受到了日本Daiichy Sankyo公司收購Ranbaxy的巨大沖擊，您對此的看法是什么呢？這能說明現(xiàn)在印度的制藥工業(yè)所處的狀態(tài)嗎？
Weldon: I could be wrong on this but I think that about 70% of drugs dispensed are generics, here in the United States today. There is a big opportunity in the generic field because of large products going off patent. But, I think that if you are a research-based company, you need to really commit yourself to research. If you are a company committed to your employees, you need to make sure that they are treated appropriately and properly and there are costs associated with that. Each company has its own choices that it has to make. Personally, I think that if you have good research, if you understand the needs of patients and if you can deliver good products into the market, that is the most important thing to be doing and that is where we’ve committed ourselves so far. But that is not to say that we wouldn’t go into generics or other companies. I think that there is a big market emerging and big opportunities in the future. Each company has its own business model that it thinks is the best; some may be both research-based and a generic company; others just research-based and others just generic-based. I think that it is an individual choice. But as the generic industry has evolved, it’s evolved into very good products. Many reputable companies are going there and feeling that that’s part of the model that they want to choose. So, I guess it’s just really a personal choice for the company.
韋爾登：也許我在這方面的看法不對，但是大約70%的配藥都是現(xiàn)今在美國很常見的藥物。由于很多藥品都沒有了專利，因而那些普通的藥物能夠給我們帶來很好的機會。但是我想，如果你是一個以研究為主的公司，那你就應該全身心投入到研究中去；如果你的公司對雇員承擔了一定的義務，那你就應該確保雇員得到了恰當?shù)拇觯蔷桶殡S著一定花費。每個公司都有其必須要作的決定。個人而言，如果你能夠作出很好的研究，如果你了解病人的需求，如果你能夠將很好的產品推廣到市場上，那就是要做的最重要的事情，那也是至今我們致力于的方向。但是那并不是說我們就不會去處理一些其他公司的事情。我想，現(xiàn)在正有一個很大的市場在顯現(xiàn)，將來也會有很大的機會。每個公司都會有自己認為做的最好的產業(yè)典 范，有些可能既是研究型又是通用型公司，有些可能只是研究型公司，也有些可能只是普通型公司。我想那是每個人作出的選擇不同。但隨著通用工業(yè)的演變，它會演變成非常好的產品。許多著名的公司到那里去，感覺那就是他們想要選擇的模型中的一部分。所以我想，那只是個人為公司作出的一個選擇。
評論
打印
